150 related articles for article (PubMed ID: 28641769)
1. Reduction of PK11195 uptake observed in multiple sclerosis lesions after natalizumab initiation.
Kaunzner UW; Kang Y; Monohan E; Kothari PJ; Nealon N; Perumal J; Vartanian T; Kuceyeski A; Vallabhajosula S; Mozley PD; Riley CS; Newman SM; Gauthier SA
Mult Scler Relat Disord; 2017 Jul; 15():27-33. PubMed ID: 28641769
[TBL] [Abstract][Full Text] [Related]
2. Increased PK11195-PET binding in normal-appearing white matter in clinically isolated syndrome.
Giannetti P; Politis M; Su P; Turkheimer FE; Malik O; Keihaninejad S; Wu K; Waldman A; Reynolds R; Nicholas R; Piccini P
Brain; 2015 Jan; 138(Pt 1):110-9. PubMed ID: 25416179
[TBL] [Abstract][Full Text] [Related]
3. A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis.
Khalid F; Tauhid S; Chua AS; Healy BC; Stankiewicz JM; Weiner HL; Bakshi R
Int J Neurosci; 2017 May; 127(5):396-403. PubMed ID: 27143245
[TBL] [Abstract][Full Text] [Related]
4. Comparison of two different methods of image analysis for the assessment of microglial activation in patients with multiple sclerosis using (R)-[N-methyl-carbon-11]PK11195.
Kang Y; Schlyer D; Kaunzner UW; Kuceyeski A; Kothari PJ; Gauthier SA
PLoS One; 2018; 13(8):e0201289. PubMed ID: 30091993
[TBL] [Abstract][Full Text] [Related]
5. PET visualization of microglia in multiple sclerosis patients using [11C]PK11195.
Debruyne JC; Versijpt J; Van Laere KJ; De Vos F; Keppens J; Strijckmans K; Achten E; Slegers G; Dierckx RA; Korf J; De Reuck JL
Eur J Neurol; 2003 May; 10(3):257-64. PubMed ID: 12752399
[TBL] [Abstract][Full Text] [Related]
6. Grey matter atrophy is associated with disability increase in natalizumab-treated patients.
Ciampi E; Pareto D; Sastre-Garriga J; Vidal-Jordana A; Tur C; Río J; Tintoré M; Auger C; Rovira A; Montalban X
Mult Scler; 2017 Apr; 23(4):556-566. PubMed ID: 27354019
[TBL] [Abstract][Full Text] [Related]
7. Microglial imaging with positron emission tomography and atrophy measurements with magnetic resonance imaging in multiple sclerosis: a correlative study.
Versijpt J; Debruyne JC; Van Laere KJ; De Vos F; Keppens J; Strijckmans K; Achten E; Slegers G; Dierckx RA; Korf J; De Reuck JL
Mult Scler; 2005 Apr; 11(2):127-34. PubMed ID: 15794383
[TBL] [Abstract][Full Text] [Related]
8. Natalizumab treatment reduces microglial activation in the white matter of the MS brain.
Sucksdorff M; Tuisku J; Matilainen M; Vuorimaa A; Smith S; Keitilä J; Rokka J; Parkkola R; Nylund M; Rinne J; Rissanen E; Airas L
Neurol Neuroimmunol Neuroinflamm; 2019 Jul; 6(4):e574. PubMed ID: 31355310
[TBL] [Abstract][Full Text] [Related]
9. In Vivo Detection of Diffuse Inflammation in Secondary Progressive Multiple Sclerosis Using PET Imaging and the Radioligand ¹¹C-PK11195.
Rissanen E; Tuisku J; Rokka J; Paavilainen T; Parkkola R; Rinne JO; Airas L
J Nucl Med; 2014 Jun; 55(6):939-44. PubMed ID: 24711650
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Effect of Fingolimod Treatment on Microglial Activation Using Serial PET Imaging in Multiple Sclerosis.
Sucksdorff M; Rissanen E; Tuisku J; Nuutinen S; Paavilainen T; Rokka J; Rinne J; Airas L
J Nucl Med; 2017 Oct; 58(10):1646-1651. PubMed ID: 28336784
[TBL] [Abstract][Full Text] [Related]
11. MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance.
Wijburg MT; Witte BI; Vennegoor A; Roosendaal SD; Sanchez E; Liu Y; Martins Jarnalo CO; Uitdehaag BM; Barkhof F; Killestein J; Wattjes MP
J Neurol Neurosurg Psychiatry; 2016 Oct; 87(10):1138-45. PubMed ID: 27530808
[TBL] [Abstract][Full Text] [Related]
12. What is the Relevance of the Systematic Use of Gadolinium During the MRI Follow-Up of Multiple Sclerosis Patients Under Natalizumab?
Bellanger G; Biotti D; Patsoura S; Ciron J; Ferrier M; Gramada R; Meluchova Z; Lerebours F; Catalaa I; Dumas H; Cognard C; Brassat D; Bonneville F
Clin Neuroradiol; 2020 Sep; 30(3):553-558. PubMed ID: 31143968
[TBL] [Abstract][Full Text] [Related]
13. Quantitative susceptibility mapping identifies inflammation in a subset of chronic multiple sclerosis lesions.
Kaunzner UW; Kang Y; Zhang S; Morris E; Yao Y; Pandya S; Hurtado Rua SM; Park C; Gillen KM; Nguyen TD; Wang Y; Pitt D; Gauthier SA
Brain; 2019 Jan; 142(1):133-145. PubMed ID: 30561514
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumab-treated multiple sclerosis.
Mellergård J; Tisell A; Blystad I; Grönqvist A; Blennow K; Olsson B; Dahle C; Vrethem M; Lundberg P; Ernerudh J
Eur J Neurol; 2017 Jan; 24(1):112-121. PubMed ID: 27699930
[TBL] [Abstract][Full Text] [Related]
15. Significant clinical worsening after natalizumab withdrawal: Predictive factors.
Vidal-Jordana A; Tintoré M; Tur C; Pérez-Miralles F; Auger C; Río J; Nos C; Arrambide G; Comabella M; Galán I; Castilló J; Sastre-Garriga J; Rovira A; Montalban X
Mult Scler; 2015 May; 21(6):780-5. PubMed ID: 25392320
[TBL] [Abstract][Full Text] [Related]
16. Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients.
Iaffaldano P; Viterbo RG; Trojano M
J Neurol; 2016 Aug; 263(8):1620-5. PubMed ID: 27260295
[TBL] [Abstract][Full Text] [Related]
17. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity.
Banati RB; Newcombe J; Gunn RN; Cagnin A; Turkheimer F; Heppner F; Price G; Wegner F; Giovannoni G; Miller DH; Perkin GD; Smith T; Hewson AK; Bydder G; Kreutzberg GW; Jones T; Cuzner ML; Myers R
Brain; 2000 Nov; 123 ( Pt 11)():2321-37. PubMed ID: 11050032
[TBL] [Abstract][Full Text] [Related]
18. Semiquantification of the peripheral-type benzodiazepine ligand [11C]PK11195 in normal human brain and application in multiple sclerosis patients.
Debruyne JC; Van Laere KJ; Versijpt J; De Vos F; Eng JK; Strijckmans K; Santens P; Achten E; Slegers G; Korf J; Dierckx RA; De Reuck JL
Acta Neurol Belg; 2002 Sep; 102(3):127-35. PubMed ID: 12400251
[TBL] [Abstract][Full Text] [Related]
19. Microglia activation in multiple sclerosis black holes predicts outcome in progressive patients: an in vivo [(11)C](R)-PK11195-PET pilot study.
Giannetti P; Politis M; Su P; Turkheimer F; Malik O; Keihaninejad S; Wu K; Reynolds R; Nicholas R; Piccini P
Neurobiol Dis; 2014 May; 65():203-10. PubMed ID: 24508617
[TBL] [Abstract][Full Text] [Related]
20. Identifying the start of multiple sclerosis injury: a serial DTI study.
Ontaneda D; Sakaie K; Lin J; Wang X; Lowe MJ; Phillips MD; Fox RJ
J Neuroimaging; 2014; 24(6):569-576. PubMed ID: 25370339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
